Cargando…
Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs
Blockchain is a novel data architecture characterized by a chronological sequence of blocks in a decentralized manner. We aimed to evaluate the real‐world feasibility of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter trial. The study consisted of three visits...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099134/ https://www.ncbi.nlm.nih.gov/pubmed/35157788 http://dx.doi.org/10.1111/cts.13246 |
_version_ | 1784706536328658944 |
---|---|
author | Huh, Ki Young Moon, Seol Ju Jeong, Sang‐un Kim, Min‐Ji Yang, Wooseok Jeong, Myeonggyu Kim, Min‐Gul Lee, SeungHwan |
author_facet | Huh, Ki Young Moon, Seol Ju Jeong, Sang‐un Kim, Min‐Ji Yang, Wooseok Jeong, Myeonggyu Kim, Min‐Gul Lee, SeungHwan |
author_sort | Huh, Ki Young |
collection | PubMed |
description | Blockchain is a novel data architecture characterized by a chronological sequence of blocks in a decentralized manner. We aimed to evaluate the real‐world feasibility of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter trial. The study consisted of three visits (i.e., screening and 2 follow‐up visits) with a 2‐week interval. Each subject was required to report the self‐measured body temperatures and take a virtual investigational drug by entering the unique drug code on the application. To simulate real‐world study settings, two major (i.e., changes in the schedule of body temperature measurement) and three minor protocol amendments (i.e., nonsignificant changes without any changes in the procedures) were set. Overall study completion rates, proportion of consent, and response time to each protocol amendment and adherence were evaluated. A total of 60 subjects (30 in each center) were enrolled in two study centers. All subjects completed the study, and the overall proportion of consent to each protocol amendment was 95.7 ± 13.7% (mean ± SD), with a median response time of 0.2 h. Overall, subjects took 90.8% ± 19.2% of the total drug, whereas compliance with the schedule was 69.1% ± 27.0%. Subjects reported 96.7% ± 4.2% of the total body temperature measurements whereas the adherence to the schedule was 59.0% ± 25.0%, which remarkably decreased after major protocol amendments. In conclusion, we evaluated a blockchain‐based dynamic consent platform in real clinical trial settings. The results suggested that major changes should be avoided unless subjects’ proper understanding is warranted. |
format | Online Article Text |
id | pubmed-9099134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90991342022-05-18 Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs Huh, Ki Young Moon, Seol Ju Jeong, Sang‐un Kim, Min‐Ji Yang, Wooseok Jeong, Myeonggyu Kim, Min‐Gul Lee, SeungHwan Clin Transl Sci Research Blockchain is a novel data architecture characterized by a chronological sequence of blocks in a decentralized manner. We aimed to evaluate the real‐world feasibility of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter trial. The study consisted of three visits (i.e., screening and 2 follow‐up visits) with a 2‐week interval. Each subject was required to report the self‐measured body temperatures and take a virtual investigational drug by entering the unique drug code on the application. To simulate real‐world study settings, two major (i.e., changes in the schedule of body temperature measurement) and three minor protocol amendments (i.e., nonsignificant changes without any changes in the procedures) were set. Overall study completion rates, proportion of consent, and response time to each protocol amendment and adherence were evaluated. A total of 60 subjects (30 in each center) were enrolled in two study centers. All subjects completed the study, and the overall proportion of consent to each protocol amendment was 95.7 ± 13.7% (mean ± SD), with a median response time of 0.2 h. Overall, subjects took 90.8% ± 19.2% of the total drug, whereas compliance with the schedule was 69.1% ± 27.0%. Subjects reported 96.7% ± 4.2% of the total body temperature measurements whereas the adherence to the schedule was 59.0% ± 25.0%, which remarkably decreased after major protocol amendments. In conclusion, we evaluated a blockchain‐based dynamic consent platform in real clinical trial settings. The results suggested that major changes should be avoided unless subjects’ proper understanding is warranted. John Wiley and Sons Inc. 2022-02-17 2022-05 /pmc/articles/PMC9099134/ /pubmed/35157788 http://dx.doi.org/10.1111/cts.13246 Text en © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Huh, Ki Young Moon, Seol Ju Jeong, Sang‐un Kim, Min‐Ji Yang, Wooseok Jeong, Myeonggyu Kim, Min‐Gul Lee, SeungHwan Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs |
title | Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs |
title_full | Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs |
title_fullStr | Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs |
title_full_unstemmed | Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs |
title_short | Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs |
title_sort | evaluation of a blockchain‐based dynamic consent platform (metory) in a decentralized and multicenter clinical trial using virtual drugs |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099134/ https://www.ncbi.nlm.nih.gov/pubmed/35157788 http://dx.doi.org/10.1111/cts.13246 |
work_keys_str_mv | AT huhkiyoung evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs AT moonseolju evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs AT jeongsangun evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs AT kimminji evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs AT yangwooseok evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs AT jeongmyeonggyu evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs AT kimmingul evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs AT leeseunghwan evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs |